Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.30 Consensus Target Price from Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received an average rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.30.

Several brokerages have recently weighed in on CGTX. Chardan Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a report on Thursday, December 19th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $1.00 to $1.50 in a report on Thursday, December 19th. Finally, HC Wainwright upped their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Mercer Global Advisors Inc. ADV raised its holdings in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after acquiring an additional 24,050 shares during the last quarter. Sigma Planning Corp raised its holdings in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after acquiring an additional 25,050 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Cognition Therapeutics in the 4th quarter worth about $26,000. Finally, Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics in the 3rd quarter worth about $27,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Trading Up 4.0 %

Shares of CGTX opened at $0.77 on Friday. The firm’s fifty day simple moving average is $0.58 and its two-hundred day simple moving average is $0.73. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95. The stock has a market capitalization of $31.96 million, a P/E ratio of -0.79 and a beta of 0.95.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.